DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript
DarioHealth NASDAQ: DRIO reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on the company's first-quarter 2026 earnings call Wednesday.
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $1.2 per share a year ago.
First quarter 2026 revenues increased to $5.6 million, marking the second consecutive quarter of sequential growth Operating expenses decreased by 21% year-over-year and decreased by 8% quarter-over-quarter Operating loss decreased by 22% year-over-year and decreased by 15% quarter-over-quarter; Non-GAAP operating loss decreased by 8% year-over-year and decreased by 11% quarter-over-quarter Channel partnerships through Solera, Amwell and other blue-chip partners provide access to over 116 million covered lives Now in contracting phase with new channel partner that, upon finalization, would extend Dario's reach to a combined 175+ million covered lives and add one of the largest hospital networks in the northeastern U.S. as a day-one anchor account 10 new accounts added during the first quarter ended March 31, 2026 — all outside the normal benefit cycle; Approximately $127 million pipeline across 241 active potential opportunities NEW YORK, May 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced financial results for the first quarter ended March 31, 2026. "The first quarter of 2026 was our second consecutive quarter of sequential revenue growth, alongside continued reductions in operating expenses.
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2026 and will host a conference call and webcast at 8:30 a.m.
Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payers NEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, titled Enhancing Workplace Outcomes Through Digital Behavioral Health Programs: Retrospective Real–World Study , demonstrated statistically significant improvements in workplace functioning among users of Dario's behavioral health solutions.
Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value NEW YORK, April 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.
DarioHealth (NASDAQ: DRIO - Get Free Report) and Thermo Fisher Scientific (NYSE: TMO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations. Insider and Institutional Ownership 33.4% of DarioHealth shares
DarioHealth (NASDAQ: DRIO) executives highlighted record commercial momentum and continued cost reductions on the company's fourth-quarter and year-end 2025 earnings call, while also addressing the revenue impact of a single legacy customer non-renewal and outlining expectations for accelerating growth through 2026. Record new agreements, but full-year revenue declined Chief Executive Officer Erez Raphael said 2025 was
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
